ADMAассоциированной патологии, и при сочетанном применении проявляют положительное фармакодинамическое взаимодействие. The study of the possibility of correcting metabolic pathway L-arginin/eNOS/NO with L-NAME-induced ADMA-associated endothelial dysfunction by means of intraperitoneal introduction tetrahydrobiopterine (BH4) in a dose of 10 mg/kg, L-arginine at a dose of 200 mg/kg, L-norvalin at a dose of 10 mg/kg and combinations of L-arginine with tetrahydrobiopterine and L-norvaline is spent. Revealed that the studied drugs separately providing endothelioprotective action at ADMA associated pathology, with the concomitant use of pharmacodynamic interaction exhibit positive. The study of the possibility of correcting metabolic pathway L-arginin/eNOS/NO with L-NAME-induced ADMA-associated endothelial dysfunction by means of intraperitoneal introduction tetrahydrobiopterine (BH4) in a dose of 10 mg/kg, L-arginine at a dose of 200 mg/kg, L-norvalin at a dose of 10 mg/kg and combinations of L-arginine with tetrahydrobiopterine and L-norvaline is spent. Revealed that the studied drugs separately providing endothelioprotective action at ADMA associated pathology, with the concomitant use of pharmacodynamic interaction exhibit positive.

The study endothelial and cardioprotective effects of antioxidants in modeling L-NAME-induced deficiency of nitric oxide. The results obtained allowed to establish express edendothelial dysfunction and prevention adrenoreactivity increasea and decrease of myocardial reserve in the experiment with the use of drugs ethoxidol 25 mg/kg resveratrol 2 mg/kg and mexidol 60 mg/kg. In this case, use of the drug resveratrol led to a significantly more pronounced reduction coefficient of endothelial.

Studying of endothelioprotective, cardioprotective and coronary activity of 3-oksipiridin derivatives, the drugs "Mexidol" and "Mexicor" was made in the laboratories of cardiofarmacology scientific research institute of Ecological medicine in experiments on rats and dogs. The received results have allowed to determine the expressed correction of endothelial dysfunction in application of the drugs "Mexidol" and "Mexicor" in a dose of 30 mg/kg. The application of "Mexicor" has allowed to achieve authentically the most expressive reducing of endothelial dysfunction quotient in comparison with the drug "Mexidol". Studying of coronary activity and influence on a frame of a phase coronary blood stream has determined, that the drugs influenced greatly on coronary activity in doses 0.25, 0.5 and 1 mg intracoronary.

Experimental NO deficiency induced by L-NAME injection led to the development of arterial hypertension, endothelial dysfunction, and cardiomyocyte hypertrophy and reduced blood content of nitrates and nitrites. Impaza, NO donors, activators of NO-synthase, antioxidants, and antihypertensive preparations produced endothelium-protective effect of different degree.

Modeling of NO deficiency by administration of L-NAME to rats led to the development of arterial hypertension and endothelial dysfunction. Pronounced endothelium and cardioprotective effects of impaza under these experimental conditions manifested more markedly during combined administration of the preparation with standard hypotensive preparations enalapril and losartan.

Studying influence of derivatives 3-oksipiridin, drugs «mexidol» and «mexicor» made to laboratories cardiofarmacology scientific research institute Ecological medicine KSMU, on indexes of collateral coronary blood flow and endothelial dysfunction in experiments on rats and dogs. The received results have allowed to position the expressed correction of endothelial dysfunction at application of drugs «mexidol» and «mexicor» in a dose of 30 mg/kg. Analysis of a collateral coronary blood flow at narcotized dogs has shown identical orientation their actions of antioxidants «mexidol» and «mexicor». At the same time, mexicor on the favorable dynamics of the majority of indexes surpassed mexidol.

In laboratory animals in nitric oxide deficiency modelling introduction of NO-syntase inhibitor L-NAME functional and biochemical markers endothelial dysfunctions factor endothelial dysfunctions, myocardial loading tests (adrenoreactivity, loading by resistance), the nitrite ions content in blood whey, expression endothelial NO-syntase investigated. Endothelioand cardioprotective effects activization of enalapril, lozartan, amlodipine, indapamide and nebivolol is revealed in their introduction in combination with L-arginine.

In tests on a group of 250 rats, we studied (i) the level of microcirculation in the muscles of a healthy limb in the norm and (ii) the dynamics of microcirculation for 6 h after treatment with pentoxifylline in a dose of 60 mg/kg dose and L-arginine in a dose of 30 and 200 mg/kg. The chronic ischemia was modeled by excision of basic femoral artery. There was no significant difference in pentoxyfilline-treated animals in comparison to the control. In the group treated with L-arginine in a dose of 30 mg/kg, a significant increase in microcirculation was observed on the 28-th day of experiment. In the group treated with L-arginine in a dose of 200 mg/kg, there was an increase of microcirculation in all terms of the experiment in comparison to the control. The results of laser doppler flow measurements are correlated with the results of morphological investigation.

We studied the effects of antioxidants resveratrol and pQ510 on physiological parameters and the state of endothelial NO-synthase as a marker of the regulatory function of the endothelium in the aorta of rats with modeled arterial hypertension. The antioxidants promoted recovery of stable NO metabolites in rat serum and maintained expression of endothelial NO-synthase at a normal level. These effects were confirmed by correction of blood pressure and endothelium-dependent vascular dilation assessed by endothelial dysfunction coefficient.

Studying of a condition of a vascular wall and search of opportunities of purposeful treatment endothelial dysfunction (ED) is the important clinic-experimental problem. One of the major factors leading to ED is reduction in stability endothelial NO-синтазы (eNOS). One of the important points of the appendix of therapeutic influence at ED is restoration of deficiency nitrice oxide (NO). However now there are no preparations for specific correction ED. The purpose of the present research was the analysis of literary data about influence of different medical products on a functional condition endothelium and studying endothelioprotective effects of a new class of the medical products positioned as a class endotheliotropic additives with recommendations to obligatory purpose-by patients with cardiovascular diseases.

The factor of endothelial dysfunction offered by us (FED), allows to estimate a degree of endothelial dysfunction at modelling deficiency nitrice oxide, that correlates with biochemical (depression of the contents nitrite-ions and expressions eNOS) and morphological (augmentation of diameter of cardiomyocytes, a spastic stricture, a thickening of a muscular layer and a desorientation of endotheliocytes of renal arterioles) markers.

It is carried out research endothelioand cardioprotective actions furostanole glycosides from culture of cells of plant Dioscorea Deltoidea (Institute of physiology of a plant of the Russian Academy of Science) conditions hypoestrogen the induced experimental dysfunction of an endothelium. Phytoestrogens from culture of cells of plant Dioscorea deltoidea prevent development hypoestrogen the induced endothelial dysfunction, rising adrenoreactivity in experiment.